Overview
The purpose of this pilot clinical trial is to confirm the efficacy and safety of Nexpowder™ for hemostasis in pilot cohort of patients with NVUGIB in Singapore
Description
24 subjects with non variceal bleeding will be enrolled. The efficacy and safety of Nexpowder™ as primary technique of endoscopci hemostasis will be assessed in this pi,ot study.
Eligibility
Inclusion Criteria:
- Males or females aged over 21 to 75 years
- Patients with confirmed nonvariceal, upper gastrointestinal bleeding
- Patients who voluntarily agree to the clinical trial with informed consent
- Patients who willing and able to comply with the study protocol
Exclusion Criteria:
- Patients with an uncorrected coagulation disorder (PLT<50*109/L, INR>2)
- Patients who are known to be pregnant or in lactation
- Patients who have received another endoscopic treatment for the same part of the body within the days preceding the study
- Patients for whom endoscopic treatment is prohibited due to comorbidity
- Patients for whom the 30-day follow-up period is impossible
- Patients who have participated within the past month in other related clinical trials that could affect the results of the study
- Other cases in which participation in the study is judged inappropriate by the investigators